The Problem
Clonal evolution doesn't happen in bulk. So why measure it that way?
Leukemias and other blood cancers evolve as competing clonal populations, each with its own mutations and protein state. Bulk methods, and even single-analyte single-cell methods, average or fragment that biology, hiding the rare clones that go on to drive resistance and relapse.
Bulk sequencing
Averages thousands of cells into one signal
Rare resistant subclones fall below the noise floor and disappear entirely, resurfacing only once relapse makes them visible in the clinic.
Single-analyte single-cell
Resolves cells, but only one layer at a time
DNA-only or protein-only methods can place a mutation in a cell, but can't tell you what that cell is actually doing.
Tapestri Triomics
DNA, RNA & protein from the same single cell
Genotype, expression, and phenotype, connected in every cell, so co-occurring mutations and their functional consequence are never averaged away.
Clinical Utility
From clonal architecture to clinical decisions
Resolving genotype and phenotype in the same cell isn't just a research advantage. It changes what a clinician can act on. In diseases like AML, single-cell multiomics distinguishes signal from noise at the moment it matters most: after treatment, when residual disease is hardest to see.
- Distinguish benign clonal hematopoiesis (CHIP) from true residual leukemia
- Detect resistance-driving clones while intervention is still possible
- Inform transplant and consolidation-therapy decisions
- Sharpen response and relapse-free survival endpoints in trials
Featured Application
Single-Cell MRD Detection in Acute Myeloid Leukemia
See how pairing genotype with immunophenotype, cell by cell, resolves the clonal complexity that standard-of-care MRD methods (flow cytometry, bulk NGS, and targeted qPCR) structurally can't.
Cell & Gene Therapy
One single-cell readout for every stage of development
As programs move from discovery toward IND, sponsors need integration safety, expression, and potency in a single assay, not three separate platforms and three separate samples. Triomics puts all three in one workflow.
DNA
Vector integration & genomic safety
Track on- and off-target edits, translocations, zygosity, and vector copy number at the resolution of a single edited cell.
RNA
Transgene & expression profiling
See exactly which edited or transduced cells are expressing your transgene, and at what level, cell by cell.
Protein
Functional potency
Pair expression with surface and intracellular protein markers to confirm the edited cell does what it's meant to do
Publications
130+ Peer-reviewed publications.
Explore the Tapestri Publication Database.
Search the growing body of research built on Tapestri, spanning clonal hematopoiesis, AML and myeloma relapse, CRISPR editing QC, and cell & gene therapy safety. Filter by application, cancer type, or journal.
Tapestri
The Tapestri Platform
The first and only single-cell technology developed to reveal the biomarkers that stratify patients, signal resistance, and identify relapse markers. With Tapestri Triomics, that multiomic readout now spans DNA, RNA, and protein from the same single cell, connecting genotype, expression, and phenotype so clonal architecture is resolved rather than averaged away.
Tapestri Platform
An end-to-end workflow from sample preparation to data visualization, keeping every cell's DNA, RNA, and protein data linked through to publication-ready insights.publication-ready insights for single-cell sequencing analysis.
Panels
Catalog and custom panels focus sequencing on the regions and targets that matter to your program, for efficient use of sequencing budget and analysis time.
News
